"Pfizer has agreed to buy the obesity startup Metsera for an enterprise value of about $4.9bn, as it seeks to catch up in a booming market after terminating the development of its own weight-loss pill for safety reasons. The US drugmaker, which has a significant presence in Ireland, will pay Metsera $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met."
"Pfizer has agreed to buy the obesity startup Metsera for an enterprise value of about $4.9bn, as it seeks to catch up in a booming market after terminating the development of its own weight-loss pill for safety reasons. The US drugmaker, which has a significant presence in Ireland, will pay Metsera $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met."
Pfizer has agreed to acquire obesity startup Metsera for an enterprise value of about $4.9bn. The deal will pay Metsera shareholders $47.50 in cash per share plus contingent payments of up to $22.50 per share tied to three specific regulatory milestones. The acquisition follows Pfizer's termination of its own weight-loss pill development on safety grounds and aims to strengthen Pfizer's position in the fast-growing obesity therapeutics market. The transaction represents a 43% premium to Metsera's closing share price and notes Pfizer's significant operational presence in Ireland.
Read at Irish Independent
Unable to calculate read time
Collection
[
|
...
]